PL1909837T3 - Kompozycja do leczenia mastocytozy układowej - Google Patents

Kompozycja do leczenia mastocytozy układowej

Info

Publication number: PL1909837T3
Authority: PL; Poland
Prior art keywords: treatment; systemic mastocytosis; mast cell; compositions; inhibitor
Prior art date: 2005-07-20

Application number

PL06764231T

Other languages

English (en)

Inventor

Peter Valent

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-20

Filing date

2006-07-19

Publication date

2010-09-30

2006-07-19 Application filed by Novartis Ag filed Critical Novartis Ag

2010-09-30 Publication of PL1909837T3 publication Critical patent/PL1909837T3/pl

Links

201000008736 Systemic mastocytosis Diseases 0.000 title abstract 4
238000011282 treatment Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
210000003630 histaminocyte Anatomy 0.000 abstract 2
208000000516 mast-cell leukemia Diseases 0.000 abstract 2
DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 abstract 2
230000002062 proliferating effect Effects 0.000 abstract 2
238000011284 combination treatment Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 abstract 1
229950010895 midostaurin Drugs 0.000 abstract 1
HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Diabetes (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cephalosporin Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

PL06764231T 2005-07-20 2006-07-19 Kompozycja do leczenia mastocytozy układowej PL1909837T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US70109805P	2005-07-20	2005-07-20
EP06764231A EP1909837B8 (en)	2005-07-20	2006-07-19	Compositions for treatment of systemic mastocytosis
PCT/EP2006/064431 WO2007010014A2 (en)	2005-07-20	2006-07-19	Compositions for treatment of systemic mastocytosis

Publications (1)

Publication Number	Publication Date
PL1909837T3 true PL1909837T3 (pl)	2010-09-30

Family

ID=37669166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06764231T PL1909837T3 (pl)	2005-07-20	2006-07-19	Kompozycja do leczenia mastocytozy układowej

Country Status (15)

Country	Link
US (1)	US8076321B2 (pl)
EP (1)	EP1909837B8 (pl)
JP (1)	JP5322639B2 (pl)
KR (1)	KR101351682B1 (pl)
CN (1)	CN101267837B (pl)
AT (1)	ATE464911T1 (pl)
AU (1)	AU2006271652B2 (pl)
BR (1)	BRPI0613863A2 (pl)
CA (1)	CA2615598C (pl)
DE (1)	DE602006013826D1 (pl)
ES (1)	ES2343542T3 (pl)
PL (1)	PL1909837T3 (pl)
PT (1)	PT1909837E (pl)
RU (1)	RU2429848C2 (pl)
WO (1)	WO2007010014A2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2943418A1 (fr) *	2009-03-17	2010-09-24	Centre Nat Rech Scient	Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
PL244930B1 (pl) *	2021-12-08	2024-04-02	Gdanski Univ Medyczny	Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2751878B1 (fr) *	1996-07-30	1998-09-04	Oreal	Utilisation dans une composition d'un extrait d'au moins une labiee
TW426516B (en) *	1996-12-06	2001-03-21	Fujisawa Pharmaceutical Co	An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
DE19857040C2 (de) *	1998-12-10	2000-12-21	Siemens Ag	Verfahren zur Detekton und Korrektur von Nichtlinearitäten hochfrequenter, spannungsgesteuerter Oszillatoren
JP2002145777A (ja) *	2000-11-06	2002-05-22	Sumitomo Pharmaceut Co Ltd	アラキドン酸誘発皮膚疾患治療剤
US20030170720A1 (en) *	2001-01-23	2003-09-11	Van Der Kuyl Antoinette Cornelia	Means and methods for treatment evaluation
EP1401429A2 (en) *	2001-06-29	2004-03-31	AB Science	Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
CA2538523A1 (en) *	2003-09-19	2005-03-31	Novartis Ag	Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
CN101693031A (zh) *	2003-11-18	2010-04-14	诺瓦提斯公司	Kit突变形式的抑制剂
WO2006135790A1 (en)	2005-06-09	2006-12-21	Bristol-Myers Squibb Company	Methods of identifying and treating individuals exhibiting mutant kit protein

2006
- 2006-07-19 WO PCT/EP2006/064431 patent/WO2007010014A2/en not_active Ceased
- 2006-07-19 AU AU2006271652A patent/AU2006271652B2/en not_active Ceased
- 2006-07-19 DE DE602006013826T patent/DE602006013826D1/de active Active
- 2006-07-19 PT PT06764231T patent/PT1909837E/pt unknown
- 2006-07-19 RU RU2008105823/15A patent/RU2429848C2/ru not_active IP Right Cessation
- 2006-07-19 BR BRPI0613863-2A patent/BRPI0613863A2/pt not_active IP Right Cessation
- 2006-07-19 CA CA2615598A patent/CA2615598C/en not_active Expired - Fee Related
- 2006-07-19 JP JP2008521973A patent/JP5322639B2/ja not_active Expired - Fee Related
- 2006-07-19 KR KR1020087003987A patent/KR101351682B1/ko not_active Expired - Fee Related
- 2006-07-19 AT AT06764231T patent/ATE464911T1/de active
- 2006-07-19 PL PL06764231T patent/PL1909837T3/pl unknown
- 2006-07-19 ES ES06764231T patent/ES2343542T3/es active Active
- 2006-07-19 CN CN2006800341476A patent/CN101267837B/zh not_active Expired - Fee Related
- 2006-07-19 US US11/996,081 patent/US8076321B2/en not_active Expired - Fee Related
- 2006-07-19 EP EP06764231A patent/EP1909837B8/en not_active Not-in-force

Also Published As

Publication number	Publication date
KR20080039915A (ko)	2008-05-07
US20090221550A1 (en)	2009-09-03
CN101267837B (zh)	2010-12-15
ATE464911T1 (de)	2010-05-15
ES2343542T3 (es)	2010-08-03
CA2615598A1 (en)	2007-01-25
JP2009501767A (ja)	2009-01-22
KR101351682B1 (ko)	2014-01-14
RU2429848C2 (ru)	2011-09-27
AU2006271652B2 (en)	2010-04-29
EP1909837B8 (en)	2010-06-02
CA2615598C (en)	2014-04-15
DE602006013826D1 (de)	2010-06-02
WO2007010014A2 (en)	2007-01-25
US8076321B2 (en)	2011-12-13
RU2008105823A (ru)	2009-08-27
WO2007010014A3 (en)	2007-06-14
PT1909837E (pt)	2010-07-07
CN101267837A (zh)	2008-09-17
EP1909837A2 (en)	2008-04-16
BRPI0613863A2 (pt)	2011-02-15
EP1909837B1 (en)	2010-04-21
JP5322639B2 (ja)	2013-10-23
AU2006271652A1 (en)	2007-01-25

Publication	Publication Date	Title
MY163477A (en)	2017-09-15	Pyrimidinyl-pyridazinone derivatives
UA99284C2 (ru)	2012-08-10	ИНГИБИТОРЫ р70 S6-КИНАЗЫ
PH12013500801A1 (en)	2014-10-20	Formulations for parenteral delivery of compounds and uses thereof
TNSN08178A1 (en)	2009-10-30	Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MXPA05010476A (es)	2005-11-16	Composiciones de inhibidores selectivos de ciclooxigenasa-2 y agonistas de 5-hidroxitripamina1b/1d para el tratamiento y prevencion de migrana.
GEP20125564B (en)	2012-06-25	Pyrimidine derivatives as kinase inhibitors
UA104731C2 (ru)	2014-03-11	Ингибиторы р38 мар-киназ
PT1940839E (pt)	2013-10-10	Inibidores de piridopirimidinona pi3k alfa
MY150136A (en)	2013-11-29	Picolinamide derivatives as kinase inhibitors
ATE430747T1 (de)	2009-05-15	2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MX2010010300A (es)	2010-10-26	Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
TW200722421A (en)	2007-06-16	Azole derivatives as inhibitors of lipases and phospholipases
MX2009008253A (es)	2009-10-12	Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
GEP201706703B (en)	2017-07-25	Boronate ester compounds and pharmaceutical compositions thereof
UA94129C2 (ru)	2011-04-11	Соединения для ингибирования митоза
MX2009006345A (es)	2009-06-23	Compuestos utiles como inhibidores de proteina cinasa.
MY159230A (en)	2016-12-30	P38 map kinase inhibitors
MX2012002480A (es)	2012-03-26	Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
EA201000089A1 (ru)	2010-06-30	Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
MXPA04004107A (es)	2004-07-23	Moleculas pequenas para el tratamiento del crecimiento celular anormal.
UA97795C2 (uk)	2012-03-26	Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
GEP20156242B (en)	2015-02-10	2-arylimidazole derivatives as pde10a enzyme inhibitors
EA201071218A1 (ru)	2011-06-30	Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
UA83875C2 (ru)	2008-08-26	Производные хинолина для применения в качестве микобактериальных ингибиторов
MX2009002842A (es)	2009-05-27	Inhibidores heterociclicos de c-met y usos de los mismos.